News | Génome Québec invests up to $500,000 to boost RNA therapeutics innovation in Quebec
Génome Québec invests up to $500,000 to boost RNA therapeutics innovation in Quebec
Génome Québec, a private, non-profit organization dedicated to advancing genomics research and innovation in Quebec, is investing up to $500,000 in McGill University’s D2R Initiative. This investment will advance the commercialization of innovative genomic technologies in Quebec through D2R’s Commercialization Priming funding program.
D2R’s Commercialization Priming funding program is designed to attract industry partners and investors while advancing genomic-based RNA therapeutic research. It provides short-term financial support to researchers to help test and validate the commercial potential of concepts, technologies, or inventions aligned with D2R priority areas: rare diseases, infectious diseases and oncology.
The Commercialization Priming program is part of a suite of D2R funding programs that support interdisciplinary research in line with D2R’s vision of delivering revolutionary genomic-based RNA therapies for all. D2R is supported by the Canada First Research Excellence Fund, as well as additional support from the Quebec Government and other philanthropic and industry partners.
“McGill’s D2R initiative is contributing significantly to advancing transformative genomics-based RNA research in the province,” said Dominique Bérubé, Vice-President, Research and Innovation at McGill University. “This investment from Génome Québec provides the vital support researchers and industry partners need for the development and biomanufacturing of novel therapeutics. We look forward to the innovations that will result from this collaboration.”
“We are thrilled to partner with D2R to accelerate genomics research applications and foster innovation in Quebec. By supporting D2R’s Commercialization Priming funding program, we aim to de-risk transformative genomic-based RNA therapeutics and capitalize on the province's strengths in genomics.” Stéphanie Lord-Fontaine, Vice President, Scientific Affairs, Génome Québec.
Génome Québec’s investment to D2R shows their commitment to enhancing Quebec’s position as a leader in RNA-based therapies. This commitment is further demonstrated through their active involvement in AReNA, a new RNA hub recently announced by the government of Quebec, which brings together key players in life sciences, including D2R and Génome Québec, to bring Quebec to the forefront of innovation in RNA therapies.
For more information about D2R and its Commercialization Priming funding program, please visit the D2R website.
#
About D2R: DNA to RNA, An inclusive Canadian approach to genomic-based RNA therapeutics
McGill University's groundbreaking research initiative, DNA to RNA (D2R), is committed to advancing genomic-based RNA therapies for those affected by infectious diseases, rare diseases or cancer. With a transformative $165 million investment from the Canada First Research Excellence Fund, alongside support from the Quebec Government, philanthropic donors, and industry partners, D2R will develop revolutionary RNA therapeutics.
For more details, visit www.mcgill.ca/dna-to-rna/
About Génome Québec:
Génome Québec’s mission is to catalyze the development and excellence of genomics research and promote its integration and democratization. It is a pillar of the Québec bioeconomy and contributes to Québec’s influence and its social and sustainable development. The funds invested by Génome Québec are provided by the ministère de l'Économie, de l'Innovation et de l’Énergie du Québec (MEIE), the government of Canada, through Genome Canada, and private partners.
To learn more, visit www.genomequebec.com.